Display options
Cite
Patel NU, Roach C, Alinia H, et al. Current treatment options for acanthosis nigricans. Clin Cosmet Investig Dermatol. 2018;11:407-413doi: 10.2147/CCID.S137527.
Patel, N. U., Roach, C., Alinia, H., Huang, W. W., & Feldman, S. R. (2018). Current treatment options for acanthosis nigricans. Clinical, cosmetic and investigational dermatology, 11407-413. https://doi.org/10.2147/CCID.S137527
Patel, Nupur U, et al. "Current treatment options for acanthosis nigricans." Clinical, cosmetic and investigational dermatology vol. 11 (2018): 407-413. doi: https://doi.org/10.2147/CCID.S137527
Patel NU, Roach C, Alinia H, Huang WW, Feldman SR. Current treatment options for acanthosis nigricans. Clin Cosmet Investig Dermatol. 2018 Aug 07;11:407-413. doi: 10.2147/CCID.S137527. eCollection 2018. PMID: 30122971; PMCID: PMC6086114.
Copy Download .nbib Format: NLM
Share it on

Clin Cosmet Investig Dermatol. 2018 Aug 07;11:407-413. doi: 10.2147/CCID.S137527. eCollection 2018.

Current treatment options for acanthosis nigricans.

Clinical, cosmetic and investigational dermatology

Nupur U Patel, Catherine Roach, Hossein Alinia, William W Huang, Steven R Feldman

Affiliations

  1. Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, [email protected].
  2. Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC.
  3. Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

PMID: 30122971 PMCID: PMC6086114 DOI: 10.2147/CCID.S137527

Abstract

Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. While the goal of therapy is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life. Treatment options for AN have not been extensively studied; however, smaller powered clinical trials and case reports exist in the literature. Our review aims to explore and evaluate the current treatment options that exist for AN.

Keywords: acanthosis nigricans; dermatologic condition; dermatology; diabetes; hyperinsulinemia; isotretinoin; malignant acanthosis; metformin; obesity; pseudoacanthosis; topical therapy; tretinoin

Conflict of interest statement

Disclosure Dr Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, and Leo Pharma Inc. Dr Feldman has received grants from Gald

References

  1. Indian Dermatol Online J. 2014 Jul;5(3):239-49 - PubMed
  2. J Drugs Dermatol. 2006 Oct;5(9):884-9 - PubMed
  3. Indian J Dermatol. 2015 Jan-Feb;60(1):103 - PubMed
  4. West Indian Med J. 2015 Mar;64(2):160-1 - PubMed
  5. Am J Clin Dermatol. 2004;5(3):199-203 - PubMed
  6. Cutis. 2010 Dec;86(6):299-302 - PubMed
  7. Horm Res. 1997;48(2):88-92 - PubMed
  8. Dermatol Ther. 2015 Jul-Aug;28(4):266 - PubMed
  9. Indian J Dermatol Venereol Leprol. 1996 May-Jun;62(3):159-61 - PubMed
  10. J Dermatolog Treat. 2008;19(6):373-5 - PubMed
  11. Arch Dermatol. 1973 Jul;108(1):133-4 - PubMed
  12. J Clin Res Pediatr Endocrinol. 2015 Mar;7(1):63-8 - PubMed
  13. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):529-30 - PubMed
  14. Cutis. 2003 Jan;71(1):33-4 - PubMed
  15. QJM. 2008 Nov;101(11):899-900 - PubMed
  16. J Dermatolog Treat. 2006;17(1):54-6 - PubMed
  17. J Am Board Fam Med. 2010 Jul-Aug;23(4):476-85 - PubMed
  18. Int J Clin Pract. 2002 Oct;56(8):578-81 - PubMed
  19. Arch Dermatol. 1991 Aug;127(8):1139-40 - PubMed
  20. J Am Acad Dermatol. 2007 Sep;57(3):502-8 - PubMed
  21. J Endocrinol Invest. 1996 Nov;19(10):699-703 - PubMed
  22. Arch Dermatol. 1980 Jan;116(1):110-1 - PubMed
  23. Arch Dermatol. 1988 Jul;124(7):1094-6 - PubMed
  24. Case Rep Pediatr. 2015;2015:934865 - PubMed
  25. J Drugs Dermatol. 2003 Dec;2(6):677-81 - PubMed
  26. J Eur Acad Dermatol Venereol. 2009 Apr;23(4):486-7 - PubMed
  27. Br J Dermatol. 1998 Nov;139(5):932-4 - PubMed
  28. Br J Dermatol. 1992 Apr;126(4):412-4 - PubMed
  29. An Bras Dermatol. 2012 Jan-Feb;87(1):97-104 - PubMed
  30. Dermatol Online J. 2008 Sep 15;14(9):2 - PubMed
  31. J Invest Dermatol. 1951 Jul;17(1):7 - PubMed
  32. Int J Obes Relat Metab Disord. 2002 May;26(5):701-9 - PubMed
  33. Dermatol Surg. 2004 Aug;30(8):1158-60 - PubMed
  34. Ann Pharmacother. 2008 Jul;42(7):1090-4 - PubMed
  35. Drugs. 1992 Apr;43(4):597-627 - PubMed
  36. J Pediatr Endocrinol Metab. 2008 Apr;21(4):339-48 - PubMed
  37. J Dermatolog Treat. 2014 Jun;25(3):223-5 - PubMed
  38. Indian J Dermatol. 2011 Nov;56(6):678-83 - PubMed

Publication Types